Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Granella

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
The Lancet. Neurology|March 22, 2020
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyAnna He, Bernd Merkel, James William L Brown, et al.
Journal of the Neurological Sciences|September 19, 2021
Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registryRachel Kenney, Mengling Liu, Sachi Patil, et al.
Multiple Sclerosis and Related Disorders|December 27, 2019
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorderAmy Kunchok, Charles Malpas, Petra Nytrova, et al.
Journal of Neurology|June 28, 2021
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara G Chisari, Giancarlo Comi, Massimo Filippi, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 1, 2019
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotypeYuan Zhou, Suzi B Claflin, Jim Stankovich, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 7, 2017
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysisAlessio Signori, Guillermo Izquierdo, Alessandra Lugaresi, et al.
Brain : a Journal of Neurology|May 10, 2020
Early clinical markers of aggressive multiple sclerosisCharles B Malpas, Ali Manouchehrinia, Sifat Sharmin, et al.
Computer Methods and Programs in Biomedicine|June 19, 2021
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progressionEdward De Brouwer, Thijs Becker, Yves Moreau, et al.
Computer Methods and Programs in Biomedicine|November 8, 2021
Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]Edward De Brouwer, Thijs Becker, Yves Moreau, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
The Lancet. Neurology|March 22, 2020
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyAnna He, Bernd Merkel, James William L Brown, et al.
Journal of the Neurological Sciences|September 19, 2021
Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registryRachel Kenney, Mengling Liu, Sachi Patil, et al.
Multiple Sclerosis and Related Disorders|December 27, 2019
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorderAmy Kunchok, Charles Malpas, Petra Nytrova, et al.
Journal of Neurology|June 28, 2021
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara G Chisari, Giancarlo Comi, Massimo Filippi, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 1, 2019
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotypeYuan Zhou, Suzi B Claflin, Jim Stankovich, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 7, 2017
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysisAlessio Signori, Guillermo Izquierdo, Alessandra Lugaresi, et al.
Brain : a Journal of Neurology|May 10, 2020
Early clinical markers of aggressive multiple sclerosisCharles B Malpas, Ali Manouchehrinia, Sifat Sharmin, et al.
Computer Methods and Programs in Biomedicine|June 19, 2021
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progressionEdward De Brouwer, Thijs Becker, Yves Moreau, et al.
Computer Methods and Programs in Biomedicine|November 8, 2021
Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]Edward De Brouwer, Thijs Becker, Yves Moreau, et al.
Pageof 12